Cargando…

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

Few therapeutic options exist for the highly aggressive triple negative breast cancers (TNBCs). In this study, we report that a contextual synthetic lethality can be achieved both in vitro and in vivo with combined EGFR and PARP inhibition with lapatinib and ABT-888, respectively. The mechanism invo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowsheen, Somaira, Cooper, Tiffiny, Stanley, Jennifer A., Yang, Eddy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469581/ https://www.ncbi.nlm.nih.gov/pubmed/23071597 http://dx.doi.org/10.1371/journal.pone.0046614

Ejemplares similares

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
por: YI, YONG WEON, et al.
Publicado: (2015)

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
por: Srinivasan, Gayathri, et al.
Publicado: (2017)

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer
por: Brough, Rachel, et al.
Publicado: (2018)

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
por: Fleury, Hubert, et al.
Publicado: (2019)

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
por: Angers, Stephane
Publicado: (2021)

Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
por: McLellan, Jessica L., et al.
Publicado: (2012)

Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy
por: Song, Won-Min, et al.
Publicado: (2023)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

XRN2 interactome reveals its synthetic lethal relationship with PARP1 inhibition
por: Patidar, Praveen L., et al.
Publicado: (2020)

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009)

Translating the role of PARP inhibitors in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2019)

Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis
por: Tanori, Mirella, et al.
Publicado: (2016)

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
por: Murata, Stephen, et al.
Publicado: (2016)

Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
por: Le, Bac Viet, et al.
Publicado: (2022)

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
por: Li, Shuangying, et al.
Publicado: (2022)

Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer
por: Zhu, Ying, et al.
Publicado: (2023)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
por: Ha, Kyungsoo, et al.
Publicado: (2014)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
por: Wang, Dong, et al.
Publicado: (2017)

Emerging Roles of Glycogen Synthase Kinase 3 in the Treatment of Brain Tumors
por: Mills, Caroline N., et al.
Publicado: (2011)

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
por: Asim, Mohammad, et al.
Publicado: (2017)

Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers
por: An, Liwei, et al.
Publicado: (2022)

Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma
por: Chen, Miaoqin, et al.
Publicado: (2022)

Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia
por: Brabson, John P., et al.
Publicado: (2023)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer
por: Inoue, Satoshi, et al.
Publicado: (2012)

Calling RNF168 to action
por: Nowsheen, Somaira, et al.
Publicado: (2018)

Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer
por: Lai, Shiue-Wei, et al.
Publicado: (2020)

DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors
por: Folly-Kossi, Helena, et al.
Publicado: (2023)

DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma
por: Weaver, Alice N., et al.
Publicado: (2015)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

Cutaneous lupus erythematosus mimicking radiation dermatitis in a patient with breast cancer
por: Nowsheen, Somaira, et al.
Publicado: (2021)

Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2023)

The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
por: Softah, Abrar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_seod0in59a2t80eri946rng7lr